These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 27936479

  • 1. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
    Best J, Bilgi H, Heider D, Schotten C, Manka P, Bedreli S, Gorray M, Ertle J, van Grunsven LA, Dechêne A.
    Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
    [Abstract] [Full Text] [Related]

  • 2. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
    Best J, Bechmann LP, Sowa JP, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A.
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic and prognostic performances of GALAD score in staging and 1-year mortality of hepatocellular carcinoma: A prospective study.
    Jitpraphawan O, Ruamtawee W, Treewatchareekorn M, Sethasine S.
    World J Gastroenterol; 2024 May 07; 30(17):2343-2353. PubMed ID: 38813057
    [Abstract] [Full Text] [Related]

  • 4. Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.
    Huang C, Xiao X, Zhou L, Chen F, Wang J, Hu X, Gao C, Clinical Laboratory Society of Chinese Rehabilitation Medicine Association, Molecular Diagnostics Society of Shanghai Medical Association, Tumor Immunology Branch of Shanghai Society for Immunology.
    J Clin Lab Anal; 2023 Dec 07; 37(23-24):e24990. PubMed ID: 38063322
    [Abstract] [Full Text] [Related]

  • 5. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
    Tayob N, Kanwal F, Alsarraj A, Hernaez R, El-Serag HB.
    Clin Gastroenterol Hepatol; 2023 Feb 07; 21(2):415-423.e4. PubMed ID: 35124267
    [Abstract] [Full Text] [Related]

  • 6. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
    Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, Saenz de Viteri C, Fobar A, Parikh ND.
    Hepatology; 2022 Mar 07; 75(3):541-549. PubMed ID: 34618932
    [Abstract] [Full Text] [Related]

  • 7. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients.
    Schotten C, Ostertag B, Sowa JP, Manka P, Bechmann LP, Hilgard G, Marquardt C, Wichert M, Toyoda H, Lange CM, Canbay A, Johnson P, Wedemeyer H, Best J.
    Pharmaceuticals (Basel); 2021 Jul 27; 14(8):. PubMed ID: 34451832
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis.
    Wang X, Zhang Y, Yang N, He H, Tao X, Kou C, Jiang J.
    Biomed Res Int; 2020 Jul 27; 2020():5087643. PubMed ID: 33015170
    [Abstract] [Full Text] [Related]

  • 10. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients.
    Shimauchi Y, Tanaka M, Kuromatsu R, Ogata R, Tateishi Y, Itano S, Ono N, Yutani S, Nagamatsu H, Matsugaki S, Yamasaki S, Tanikawa K, Sata M.
    Oncol Rep; 2000 Jul 27; 7(2):249-56. PubMed ID: 10671666
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
    Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, Takasaki K, Nakano M.
    J Gastroenterol Hepatol; 2002 Jul 27; 17(7):772-8. PubMed ID: 12121507
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma.
    Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS.
    Hepatology; 2019 May 27; 69(5):1983-1994. PubMed ID: 30153338
    [Abstract] [Full Text] [Related]

  • 16. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.
    Li H, Liu H, Yan LJ, Ding ZN, Zhang X, Pan GQ, Han CL, Tian BW, Tan SY, Dong ZR, Wang DX, Yan YC, Li T.
    Expert Rev Gastroenterol Hepatol; 2023 May 27; 17(11):1159-1167. PubMed ID: 37929312
    [Abstract] [Full Text] [Related]

  • 17. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.
    Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N.
    J Gastroenterol; 2010 Dec 27; 45(12):1272-82. PubMed ID: 20625772
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.